Drugs / SAN-300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02047604 | Dec 2013 → Feb 2017 | rheumatoid arthritis | Bausch Health Americas, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAN-300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02047604 ↗ |
| Known as | Anti-vla-1 antibody - salix | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297822 ↗ |
| Route | Subcutaneous | “SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks” NCT02047604 ↗ |